Edmonton Symptom Assessment Scale may reduce medical visits in patients undergoing chemotherapy for breast cancer

作     者：Valeria Sanna Palma Fedele Giulia Deiana Maria G Alicicco Chiara Ninniri Anna N Santoro Antonio Pazzola Alessandro Fancellu 

作者机构：Unit of Medical OncologyA.O.U.SassariSassari 07100Italy Unit of Medical OncologyHospital“D.Camberlingio”Francavilla Fontana 72100BrindisiItaly Department of MedicalSurgical and Experimental SciencesUnit of General Surgery 2-Clinica ChirurgicaUniversity of SassariSassari 07100Italy 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2022年第13卷第7期

页      面：577-586页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Edmonton system assessment scale Adjuvant chemotherapy Breast cancer Medical visits Patient-reported outcomes 

摘      要：BACKGROUND Adjuvant chemotherapy is recommended in high-risk breast cancer. However, no universally accepted guidelines exist on pre-chemotherapy assessment. In particular, the number and frequency of medical visits vary according to each institution’s policy. We hypothesised that the Edmonton Symptom Assessment Scale(ESAS) may have a favourable impact on the pre-treatment assessment in candidates for adjuvant *** To investigate whether the ESAS can be used to safely reduce the number of medical visits in women with breast cancer undergoing adjuvant *** In a retrospectively prospective matched-pair analysis, 100 patients who completed the ESAS questionnaire before administration of adjuvant chemotherapy(ESAS Group) were compared with 100 patients who underwent chemotherapy according to the traditional modality, without ESAS(no-ESAS Group). Patients of the ESAS Group received additional visits before treatment if their ESAS score was 3. The primary endpoint was the total number of medical visits during the entire duration of the chemotherapy period. The secondary endpoints were the occurrence of severe complications(grade 3-4) and the number of unplanned visits during the chemotherapy *** The study variables did not statistically differ between patients of the ESAS Group and no-ESAS Group(age P = 0.880;breast cancer stage P = 0.56;cancer histology P = 0.415;tumour size P = 0.258;lymph node status P = 0.883;immunohistochemical classification P = 0.754;type of surgery P = 0.157), except for premenopausal status(P = 0.015). The study variables did not statistically differ between patients of the ESAS Group and no-ESAS Group regarding age, cancer stage, histology, tumour size, lymph node status, immunohistochemical classification, and type of surgery. Unplanned visits during the entire duration of chemotherapy were 8 in the ESAS Group and 18 in the no-ESAS Group visits(P = 0.035). Grade 3-4 toxicity did not differ between the st